New hope for lung cancer patients who failed standard treatment
NCT ID NCT07442565
First seen Mar 03, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) in people with a certain type of advanced lung cancer (non-squamous non-small cell) that no longer responds to standard treatments. About 506 adults will be randomly assigned to receive either SYS6010 or docetaxel. The main goal is to see if SYS6010 helps people live longer without their cancer growing, and to compare side effects and quality of life between the two treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.